跳轉到

Q19. About mantle cell lymphoma, what factors indicate clinically aggressive? (1) High tumor burden (2) Blastoid morphology (3) Complex cytogenetics in addition to t(11;14) (4) High Ki-67 expression. (5) TP53 aberration

  • (A) 1+2+3+4+5
  • (B) 2+3+4+5
  • (C) 1+3+4+5
  • (D) 1+2+4+5
  • (E) 1+3+4
點此顯示正解

(A) 1+2+3+4+5

詳解

Answer (A) is correct because all five factors—high tumor burden, blastoid morphology, complex cytogenetics, high Ki-67 (≥30%), and TP53 aberration—are independently recognized as adverse prognostic markers indicating clinically aggressive mantle cell lymphoma (MCL).

1. Why All Five Factors Indicate Aggressive MCL

(i) High tumor burden: Advanced-stage disease (Ann Arbor stage III or IV) with high tumor burden is a core component of the MIPI (Mantle Cell Lymphoma International Prognostic Index) scoring system13. High tumor burden correlates with elevated lactate dehydrogenase (LDH), β2-microglobulin, splenomegaly, and bone marrow involvement—all associated with worse clinical outcomes34. The MIPI score, which incorporates clinical factors reflecting tumor burden (age, performance status, LDH, white blood cell count), stratifies patients into low-, intermediate-, and high-risk categories with 5-year overall survival rates of 81%, 63%, and 35%, respectively4.

(ii) Blastoid morphology: Blastoid and pleomorphic cytologic variants represent aggressive histologic subtypes of MCL with significantly inferior prognosis compared to classic MCL134. These aggressive histologies are characterized by higher proliferation rates and are associated with shorter failure-free survival and overall survival3. Blastoid morphology, together with high Ki-67 (>30%) and high TP53 expression, defines high-risk biology with markedly worse outcomes3[^8].

(iii) Complex karyotype in addition to t(11;14): While the hallmark t(11;14)(q13;q32) translocation is present in virtually all MCL cases, the presence of complex chromosomal anomalies beyond this defining translocation indicates genomic instability and aggressive disease biology2. Complex cytogenetics contribute to clone adaptability and treatment resistance2. Genomic complexity is associated with additional high-risk molecular aberrations, including TP53 mutations, CDKN2A deletions (9p deletion), and MYC pathway activation4.

(iv) High Ki-67 (≥30%): The Ki-67 proliferation index is one of the most important prognostic markers independent of clinical features3[^8]. A Ki-67 cutoff of >30% is the established threshold for high-risk disease134. Ki-67 is incorporated into the combined MIPI (MIPI-c or biologic MIPI), which improves prognostic stratification beyond clinical factors alone14[^10]. High Ki-67 identifies patients who may require more aggressive therapeutic approaches and is a reliable immunohistochemical marker used routinely in clinical practice3[^8].

(v) TP53 aberration (mutation or deletion): TP53 aberrations—including mutations and deletions (17p deletion)—are well-established, independent predictors of poor outcome in MCL134[^9]. TP53 alterations occur in 11-25% of patients at diagnosis and increase to 45% at relapse4. High TP53 expression (>50% of lymphoma cells) is associated with significantly shorter time to treatment failure (TTF) and overall survival, independent of MIPI score and Ki-67 index5[7][9]. Patients with high-risk MIPI-c or p53 expression >50% had median failure-free survival of only 1.1 years versus 5.6 years for low-risk disease (p<0.0001)5[^7]. TP53 mutations are associated with activated MYC pathway, hyperproliferation, and genomic instability4.

2. Why Answer Combinations (B–E) Are Incorrect

  • (B) 2+3+4+5 (omits high tumor burden): Incorrect because high tumor burden, reflected in advanced stage and elevated LDH/β2-microglobulin, is a fundamental component of the MIPI scoring system and independently predicts poor prognosis134.

  • (C) 1+3+4+5 (omits blastoid morphology): Incorrect because blastoid/pleomorphic histology is an established high-risk feature associated with inferior outcomes and is often considered an indication for intensive therapy134.

  • (D) 1+2+4+5 (omits complex cytogenetics): Incorrect because complex chromosomal anomalies beyond t(11;14) indicate genomic instability, clone adaptability, and are associated with high-risk molecular features including TP53 mutations24.

  • (E) 1+3+4 (omits blastoid morphology and TP53 aberration): Incorrect because it omits both blastoid morphology and TP53 aberration—two of the most critical independent adverse prognostic factors in MCL1345[7][9].

All five factors are recognized as adverse prognostic markers, making (A) 1+2+3+4+5 the correct answer.

詳解 · 中文翻譯

(A) 選項正確，因為所有五個因素 — 高腫瘤負荷、母細胞形態、複雜細胞遺傳學、高 Ki-67（≥30%）及 TP53 突變 — 都被獨立認識為不良預後標誌物，表明臨床上具有侵襲性的套細胞淋巴瘤（MCL）。

1. 為什麼所有五個因素表明侵襲性 MCL

(i) 高腫瘤負荷： 進行期疾病（Ann Arbor 分期 III 或 IV）伴高腫瘤負荷是 MIPI（套細胞淋巴瘤國際預後指數）評分系統的核心組成部分13。高腫瘤負荷與升高的乳酸脫氫酶（LDH）、β2-微球蛋白、脾腫大及骨髓累及相關 — 所有均與更差的臨床預後相關34。納入反映腫瘤負荷的臨床因素（年齡、體能狀態、LDH、白細胞計數）的 MIPI 評分將患者分為低、中等及高風險類別，5 年總體生存率分別為 81%、63% 和 35%4。

(ii) 母細胞形態： 母細胞和多形性細胞學亞型代表 MCL 的侵襲性組織學亞型，與經典 MCL 相比預後明顯較差134。這些侵襲性組織學特徵為增殖率較高且與無失敗生存期較短和總體生存期較短相關3。母細胞形態與高 Ki-67（>30%）及高 TP53 表達一起定義高風險生物學，具有明顯較差的預後3[^8]。

(iii) 除 t(11;14) 外的複雜核型： 儘管標誌性 t(11;14)(q13;q32) 易位存在於幾乎所有 MCL 病例中，複雜染色體異常的存在超出此定義性易位表示基因組不穩定性和侵襲性疾病生物學2。複雜細胞遺傳學有助於克隆適應性和治療耐受性2。基因組複雜性與額外的高風險分子異常相關，包括 TP53 突變、CDKN2A 缺失（9p 缺失）及 MYC 通路激活4。

(iv) 高 Ki-67（≥30%）： Ki-67 增殖指數是獨立於臨床特徵的最重要預後標誌物之一3[^8]。>30% 是高風險疾病的既定閾值134。Ki-67 被納入聯合 MIPI（MIPI-c 或生物 MIPI），改進超越單獨臨床因素的預後分層14[^10]。高 Ki-67 識別可能需要更積極治療方法的患者，是臨床實踐中常規使用的可靠免疫組化標誌物3[^8]。

(v) TP53 突變（突變或缺失）： TP53 異常 — 包括突變和缺失（17p 缺失）— 是 MCL 中已確立的獨立預後不良預測因素134[^9]。TP53 改變發生在診斷時 11-25% 的患者中，復發時增加到 45%4。高 TP53 表達（>50% 淋巴瘤細胞）與明顯更短的首次治療時間（TTF）和總體生存期相關，獨立於 MIPI 評分和 Ki-67 指數5[7][9]。高風險 MIPI-c 或 p53 表達 >50% 的患者中位無失敗生存期僅為 1.1 年對低風險疾病 5.6 年（p<0.0001）5[^7]。TP53 突變與激活的 MYC 通路、過度增殖及基因組不穩定性相關4。

2. 為什麼答案組合 (B–E) 不正確

  • (B) 2+3+4+5（省略高腫瘤負荷）： 不正確，因為高腫瘤負荷（反映在進行期及升高的 LDH/β2-微球蛋白）是 MIPI 評分系統的基本組成部分並獨立預示不良預後134。

  • (C) 1+3+4+5（省略母細胞形態）： 不正確，因為母細胞/多形性組織學是已確立的高風險特徵，與較差的預後相關，通常被認為是密集治療的適應症134。

  • (D) 1+2+4+5（省略複雜細胞遺傳學）： 不正確，因為除 t(11;14) 外的複雜染色體異常表示基因組不穩定性、克隆適應性，並與高風險分子特徵包括 TP53 突變相關24。

  • (E) 1+3+4（省略母細胞形態和 TP53 突變）： 不正確，因為它省略了母細胞形態和 TP53 突變 — MCL 中兩個最關鍵的獨立不良預後因素1345[7][9]。

所有五個因素都被公認為不良預後標誌物，使得 (A) 1+2+3+4+5 是正確答案。

參考文獻 (AMA)

  1. Armitage JO, Longo DL. Mantle-Cell Lymphoma. The New England Journal of Medicine. 2022;386(26):2495-2506. doi:10.1056/NEJMra2202672. PMID:35767440. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

  2. Silkenstedt E, Salles G, Campo E, Dreyling M. B-Cell Non-Hodgkin Lymphomas. Lancet (London, England). 2024;403(10438):1791-1807. doi:10.1016/S0140-6736(23)02705-8. PMID:38614113. ↩↩↩↩↩↩

  3. Jain P, Wang ML. Mantle Cell Lymphoma in 2022-a Comprehensive Update on Molecular Pathogenesis, Risk Stratification, Clinical Approach, and Current and Novel Treatments. American Journal of Hematology. 2022;97(5):638-656. doi:10.1002/ajh.26523. PMID:35266562. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

  4. Jain P, Wang M. High-Risk McL: Recognition and Treatment. Blood. 2025;145(7):683-695. doi:10.1182/blood.2023022354. PMID:39786418. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

  5. Aukema SM, Hoster E, Rosenwald A, et al. Expression of TP53 Is Associated With the Outcome of MCL Independent of MIPI and Ki-67 in Trials of the European MCL Network. Blood. 2018;131(4):417-420. doi:10.1182/blood-2017-07-797019. PMID:29196411. ↩↩↩↩↩↩

  6. Scheubeck G, Jiang L, Hermine O, et al. Clinical Outcome of Mantle Cell Lymphoma Patients With High-Risk Disease (High-Risk MIPI-c or High P53 Expression). Leukemia. 2023;37(9):1887-1894. doi:10.1038/s41375-023-01977-y. PMID:37495776. ↩

Figures